
    
      This is an open-label, dose-escalation study PhaseI Treatments repeats for 28 days for 1
      course in the unacceptable toxicity

      Cohort of 3 patients receive escalating doses of Z-208 until the maximum tolerated dose (MTD)
      is determined. The MTD is defined as the dose preceding that at which 1 of 3 patients
      experience dose-limiting toxicity.

      PhaseII Treatments repeats for 28 days for 6 courses until absence of disease progression or
      unacceptable toxicity.
    
  